Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma

The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.

Trial Details

NCT ID
NCT07603375
Phase
PHASE2
Sponsor
Duke University
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Locations (sample)
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Subject must be able to provide study specific informed consent prior to study entry
  • Must be newly diagnosed, histologically proven diagnosis of adenocarcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II);
  • Stage II-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition;
  • Complete history and physical examination within 21 days of signing consent;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →